Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : SERUM1 Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362679 Received : Dec 25, 2024, 04:54 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:56 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Lipid Profile
Cholesterol - Total 204 mg/dL <200 : Desirable
(Method: Cholesterol Oxidase, Esterase, peroxidase)
200-239 : Borderline risk
>240 : High risk
Cholesterol - HDL 45 mg/dL > 65 : No Risk
(Method: Enzymatic Colorimetric)
45 - 65 : Moderate Risk
< 55 High Risk
Cholesterol - LDL 115.40 mg/dL < 100 : Normal
(Method: Calculated)
100 - 129 : Desirable
130 – 159 : Borderline-High
160 – 189 : High
> 190 : Very High
Cholesterol VLDL 43.60 mg/dL 7 - 40
(Method: Calculated)
Triglycerides 218.0 mg/dL < 150 :Normal
(Method: Lipase / Glycerol Kinase)
150–199 :Borderline-High
200–499 :High
> 500 :Very High
Cholesterol - Non-HDL 159 mg/dL < 130 mg/dl: Desirable
(Method: Calculated)
Total cholesterol/HDL 4.53 Ratio 0 - 5.0
(Method: Calculated)
LDL / HDL 2.56 Ratio 0 - 3.5
(Method: Calculated)
Interpretation:
• For non-fasting samples, the biological reference interval remains the same for all parameters, except of triglyceride as cholesterol (HDL, LDL, total), which changes
only by a small amount in the non-fasting state; the recommended desired value for triglyceride is <175 mg/dl. In the non-sting state, individuals with a non-fasting
triglyceride level >200 mg/dl, are recommended to perform a follow-up fasting lipid panel in 2 to 4 weeks.
• As per the consensus of the Lipid Association of India, non-HDL cholesterol and LDL cholesterol can be used as targets to monitor the effectiveness of lipid-lowering
therapy.
Associated tests: Apolipoproteins A1, Apolipoproteins B, Apolipoprotein B/A1 Ratio, Lipoprotein(a)
**END OF REPORT**
Page 1 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : SERUM1 Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362679 Received : Dec 25, 2024, 04:54 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:57 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Liver Function Profile
Bilirubin Total 0.3 mg/dL Up to 0.9
(Method: Diazo Method)
Bilirubin Direct 0.1 mg/dL 0 - 0.30
(Method: Diazo method)
Bilirubin Indirect 0.20 mg/dL 0 - 1.0
(Method: Calculated)
Alkaline Phosphatase (ALP) 53 U/L 35 - 104
(Method: PNPP, AMP Buffer)
Alanine Transaminase (ALT/SGPT) 24.3 U/L 10 - 35
(Method: UV without pyridoxal -5- phosphate)
Aspartate Aminotransferase(AST/SGOT) 18 U/L 10 - 35
(Method: IFCC Without Pyridoxal Phosphate)
Y- Glutamyl Transferase (GGT) 44 U/L 6 - 42
(Method: glutamyl-carboxynitroanilide)
Protein Total 7.2 g/dL 6.6 - 8.7
(Method: Biuret)
Albumin 4.67 g/dL 3.97 - 4.94
(Method: Bromcresol Green)
Globulin 2.53 g/dl 2.5 - 3.5
(Method: Calculated)
Albumin/Globulin 1.85 Ratio 1.0 - 2.1
(Method: Calculated)
Interpretation:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity(AST & ALT),synthesis and secretion of bile (Bilirubin ,ALP),cholestasis (ALP,GGT),protein synthesis (Albumin).
1. Hepatocellular injury:
• AST-Elevated levels can be seen. However,it is not specific to liver and can be raised in cardiac and skeletal injuries.
• ALT -Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury.
Values also correlate well with increasing BMI.
• Disproportinate increase in AST,ALT compared with ALP.
• Bilirubin may be elevated.
• AST: ALT (ratio) - In case of hepatocellular injury AST : ALT >1
In Alcoholic Liver Disease AST : ALT usually >2
This ratio is also seen to be increased in NAFLD ,Wilsons's disease, Cirrhosis ,but the increase is usually not >2
2. Cholestatic pattern:
• ALP - Disproportinate increase in ALP compared with AST,ALT.
• Bilirubin may be elevated.
• ALP elevation also seen in pregnancy,impacted by age and sex.
• To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
3. Synthesis function impairment:
• Albumin - Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time ) helps.
**END OF REPORT**
Page 2 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : SERUM1 Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362679 Received : Dec 25, 2024, 04:54 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:56 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Creatinine 0.7 mg/dL 0.50 - 0.90
(Method: Jaffe Kinetic)
Urea 17 mg/dL 16.6 - 48.5
(Method: Urease)
Blood Urea Nitrogen (BUN) 7.94 mg/dL 6 - 20
(Method: Calculated)
Blood Urea Nitrogen (BUN)/Creatinine 11.34 Ratio 6 - 22
(Method: Calculated)
Sodium 142 mmol/L 135 - 145
(Method: ISE)
Potassium 4.3 mmol/L 3.8 - 5.2
(Method: ISE)
Chloride 99 mmol/L 95 - 105
(Method: ISE)
Uric Acid 4.2 mg/dL 2.4 - 6.6
(Method: Uricase)
Glomerular Filtration Rate (eGFR) 110.69 mL/min 90 - 120 mL/min/1.73 m2
(Method: Calculated)
Interpretation:
Creatinine: Muscles produce creatinine, a waste product, from creatine phosphate, a substance that stores a lot of energy. Unlike urea, the amount of
creatinine generated is constant and mostly depends on muscle mass. Age, gender, race, muscularity, exercise, pregnancy, and several other
physiulogical characteristics can all have an impact on serum creatinine levels. Decreased serum Creatinine is associated with increasing Age and poor
muscle mass, such as muscular atrophy. Both acute and chronic renal disease and blockage are associated with elevated blood creatinine levels.
Creatinine is not an appropriate indicator for identifying kidney disease in its early stages since an increase in blood creatinine is only seen when there is
significant nephron damage.
High Urea, Uric Acid, and Blood Urea Nitrogen (BUN) could indicate poor renal function, in addition to other etiulogies
Sodium:
• Low levels: prulonged vomiting or diarrhea, diminished reabsorption in the kidney, and excessive fluid retention. Pseudo-hyponatremia is a
laboratory artifact. It is usually caused by hypertriglyceridemia, chulestasis (lipoprotein X), and hyperproteinemia (monoclonal gammopathy,
intravenous immunoglobulin [IVIG]). Diluted sampling should also be suspected in such cases and confirmed on a repeat fresh sample if indicated
clinically.
• High levels: excessive fluid loss, high salt intake, and increased kidney reabsorption.
Potassium:
• Low levels: reduced intake of dietary potassium or excessive loss of potassium from the body due to diarrhea, prulonged vomiting, or increased
renal excretion.
• High levels: dehydration or shock, severe burns, hemulysis, diabetic ketoacidosis, and retention of potassium by the kidney. Pseudohyperkalemia,
which may result from a hemulyzed or aged sample, should always be ruled out by doing a repeat electrulyte estimation on a fresh
sample, as clinically indicated.
Chloride:
• Low levels are noted in reduced dietary intake, prulonged vomiting, and reduced renal reabsorption, as well as some forms of acidosis and alkalosis.
• High levels are found in dehydration, kidney failure, some forms of acidosis, high dietary or parenteral chloride intake, and salicylate poisoning
An estimated glomerular filtration rate (eGFR) test is an indicator of how well kidneys filter waste and toxins from blood.
**END OF REPORT**
Page 3 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : SERUM1 Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362679 Received : Dec 25, 2024, 04:54 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:57 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
IRON PROFILE
Iron 58 µg/dL 33 - 193
(Method: Ferrozine – without Deproteinization)
UIBC 265.3 µg/dL 155 - 355
(Method: Nitroso-PSAP)
Iron Binding Capacity - Total (TIBC) 323.30 µg/dL 240 - 450
(Method: Calculated)
Transferrin 219.93 ug/dL 176 - 280
(Method: Calculated)
Transferrin % 17.94 % 20 - 50
(Method: Calculated)
**END OF REPORT**
Page 4 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : SERUM1 Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362679 Received : Dec 25, 2024, 04:54 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:46 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Thyroid Profile-II
Triiodothyronine Total (TT3) 92.4 ng/dL 80 - 200
(Method: CLIA)
Triiodothyronine Free (FT3) 3.21 pg/mL 2.3 - 4.2
(Method: CLIA)
2.0 - 3.8: Pregnancy
Thyroxine - Total (TT4) 6.79 ug/dL 5.1 - 14.1
(Method: CLIA)
Thyroxine - Free (FT4) 1.17 ng/dL 0.8 - 2.7: Adults
(Method: CLIA)
Pregnancy
0.7 - 2.0: First Trimester
0.5 - 1.6: 2nd and 3rd Tri
Thyroid Stimulating Hormone (TSH) 3.52 uIU/mL Adults : 0.27 - 4.2
(Method: CLIA)
First trimester : 0.3 - 4.5
Second Trimester :0.5 - 4.6
Third Trimester : 0.8 - 5.2
Interpretation:
Important Note:
A TSH value of up to 15 µIU/ml needs clinical correlation or repeat testing with a new sample, as physiological factors can give falsely high TSH.
Transiently Raised TSH can occur due to non-thyroid illnesses like severe infections liver, cardiac, and kidney diseases, burns, surgery, and trauma.
Diurnal Variability: TSH Follows a Diurinal rhythm and is at maximum between 2 am to 4 am and a minimum between 6 to 10 pm. Variation is about
50-206%.
Limitations:
• Patients receiving High Biotin Dose treatment should have a gap of a minimum of 8 hrs, before giving the blood sample.
• Heterophile Antibodies can react in Immunoassay procedures giving erroneous results. The assay is designed to minimize heterophile antibody
interference.
Please Note: FT3 and FT4 Measure the free "unbound" fraction of the T3 and T4 and are considered more sensitive compared to the Total T3 and T4 to
assess thyroid status.
Associated tests: Anti-thyroid Antibodies, USG thyroid, TSH receptor Antibody. Thyroglobulin, Calcitonin.
**END OF REPORT**
Page 5 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : WB EDTA* Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362678 Received : Dec 25, 2024, 04:55 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:41 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Glycosylated Hemoglobin (GHb/HBA1c)
HbA1c 5.1 % < 6.0 : Non Diabetic
(Method: HPLC)
6.1 – 6.5 : Prediabetic
6.6 – 7.0 : Good Control
7.1-8.0 : POOR Control
>8.1 : ALERT
Estimated Average Glucose (eAG) 99.67 % 70 - 136
Interpretation:
Excellent Control: 6 to 7 %
Fair to Good Control: 7 to 8 %
Unsatisfactory Control: 8 to 10 %
and Poor Control: More than 10%.
Factors Influencing HbA1c Results: Increased levels: Elevated fetal hemoglobin, chronic renal failure, iron deficiency anemia, splenectomy,
heightened serum triglycerides, alcohol consumption, poisoning (Lead, Opiate), and salicylate therapy. Decreased levels: are often associated with
systemic inflammatory diseases and reduced RBC life span, severe iron deficiency & haemolytic anaemia, chronic renal failure, and liver diseases.
Clinical correlation reduced red blood cell lifespan (such as in hemolytic anemia or blood loss), following blood transfusions, during pregnancy, excessive
intake of Vitamin E or Vitamin C, and hemoglobinopathies, For HbF > 25% and homozygous hemoglobinopathy, an alternate platform (Fructosamine) is
recommended for testing of HbA1c.
• HbA1c, also known as glycosylated hemoglobin or glycated hemoglobin, refers to hemoglobin that has glucose molecules attached. It gives an
average of glucose levels in the bloodstream for the preceding 2 to 3 months.
• HbA1c has been endorsed by clinical groups & ADA (American Diabetes Association) guidelines for the diagnosis of diabetes using a cut-off point of
6.5%.
• For diabetic patients achieving treatment objectives, the HbA1c test should be conducted at least biannually. If treatment objectives are not met or if
a new regimen is initiated, testing once every 3 months is recommended.
• The HbA1c target for non-pregnant adults is generally set at below 7% to prevent microvascular complications.
• In known diabetic patients, the following values can be considered as a tool for monitoring glycemic control.
Associated tests: HOMA IR index, insulin, C-peptide levels.
**END OF REPORT**
Page 6 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : SERUM1 Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362679 Received : Dec 25, 2024, 04:54 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:57 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Calcium & Phosphorus
Calcium 9.5 mg/dL 8.6 - 10.0
(Method: NM-Bapta complex)
Interpretation:
The diagnosis and monitoring of a wide range of disorders including diseases of bone, kidney, parathyroid gland, or gastrointestinal
tract Calcium levels may also reflect abnormal vitamin D or protein levels. Calcium ions affect the contractility of the heart and the
skeletal musculature, and are essential for the function of the nervous system. In addition, calcium ions play an important role in
blood clotting and bone mineralization.
Hypocalcemia is due to the absence or impaired function of the parathyroid glands or impaired vitamin-D synthesis. Chronic renal
failure is also frequently associated with hypocalcemia due to decreased vitamin-D synthesis as well as hyperphosphatemia and
skeletal resistance to the action of parathyroid hormone (PTH). A characteristic symptom of hypocalcemia is latent or manifest
tetany and osteomalacia.
Phosphorus 4.9 mg/dL 2.5 - 4.5
(Method: Phosphomolybdate - UV)
**END OF REPORT**
Page 7 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : WB EDTA* Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362678 Received : Dec 25, 2024, 04:55 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:22 p.m.
HAEMATOLOGY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Complete Blood Count (CBC)
Erythrocytes (EDTA, Whole Blood)
Hemoglobin (Hb)* 11 g/dL 12.0 - 15.0
(Method: Photometry)
Erythrocyte Count (RBC Count) 4.3 mil/µL 3.8 - 4.8
(Method: Electronic Impedance)
Packed Cell Volume(Hematocrit) 38 % 36 - 46
(Method: Calculated)
MCV 87 fl 83 – 101
MCH 26 pg 27 – 32
MCHC 29.4 g/dL 31.5 – 34.5
RDW-CV 23.7 % 11.6 - 14.5
RDW-SD 71.0 fL 40.0 - 55.0
RBC Morphology
Remarks Normocytic normochromic, anisocytosis Noted
Leucocytes
Total Leucocyte Count (WBC) 2340 cells/Cumm 4000 - 10000
Neutrophils 47 % 40 - 80
Lymphocytes 39 % 20 – 40
Eosinophils 4 % 1–6
Monocytes 10 % 2 - 10
Basophils 0 % 0–1
Absolute Count
Absolute Neutrophil Count 1.1 * 10^9/L 2.0 - 7.0
(Method: Calculated)
Absolute Lymphocyte Count 1 * 10^9/L 1-3
(Method: Calculated)
Absolute Monocyte Count 0.3 * 10^9/L 0.2 - 1.0
(Method: Calculated)
Absolute Eosinophil Count 0.1 * 10^9/L 0.0-0.5
(Method: Calculated)
Absolute Basophils Count 0.00 * 10^9/L 0.02-0.10
(Method: Calculated)
WBC Morphology Leucopenia
Platelets
Platelet Count 262 10^3/uL 150 - 450
(Method: Electronic Impedance)
Page 8 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : WB EDTA* Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362678 Received : Dec 25, 2024, 04:55 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:22 p.m.
HAEMATOLOGY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Mean Platelet Volume (MPV) 8.5 fL 7.2 - 11.7
Platelet Morphology Adequate on smear
PDW 12 % 9 - 17
PCT 0.2 % 0.2 - 0.5
(Method: Calculated)
Platelet large cell ratio (P-LCR) 26.7 % 15 - 35
Tests done on Automated Five Part Cell Counter. (WBC, RBC,Platelet count by impedance method, colorimetric method for
Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal
Haemograms are reviewed confirmed microscopically.
**END OF REPORT**
Page 9 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : Naf Plasma Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362677 Received : Dec 25, 2024, 04:55 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:34 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Glucose - Fasting
Glucose - FBS 117 mg/dL 70 - 109
(Method: Hexokinase)
Interpretation:
Blood glucose test may be used to detect high blood glucose (hyperglycemia) and low blood glucose (hypoglycemia).Screen for diabetes in people who are at risk before signs
and symptoms are apparent; in some cases, there may be no early signs or symptoms of diabetes. Screening can therefore be useful in helping to identify it and allowing for
treatment before the condition worsens or complications arise,Help diagnose diabetes, prediabetes and gestational diabetes,Monitor glucose levels in people diagnosed with
diabetes.
**END OF REPORT**
Page 10 of 11
Made with Xodo PDF Reader and Editor
Name : MRS. ANITHA H G
Age/Gender : 43 years / Female Ref. Doctor : SELF MEDID : 238544
Sample Type : Plasma Naf Collected : Dec 25, 2024, 03:02 p.m.
Sample ID : 243362676 Received : Dec 25, 2024, 04:55 p.m.
Client Name : 1KABLR226 Reported : Dec 25, 2024, 05:23 p.m.
CLINICAL BIOCHEMISTRY
TEST DESCRIPTION RESULT UNITS REFERENCE RANGES
Glucose - Postprandial
Glucose - PLBS 90 mg/dL 90 - 160
(Method: Hexokinase)
**END OF REPORT**
Page 11 of 11
